News 28.07.2026 Schlieren, Switzerland, 21 July 2026 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced a distribution partnership with Europa Biosite, a leading distributor of life science research products and services. Through this partnership, Europa Biosite will distribute arcoris bio’s newly launched immunoMUSE® kits in...
News 22.07.2026 Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the development of its R&D pipeline. “Neurimmune’s financial strategy is based on non-dilutive income...
News 16.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces the...
News 07.07.2026 Microcaps AG, the Swiss precision microencapsulation company, announced today a strategic collaboration and equity investment from Givaudan, the global leader in Fragrance & Beauty. This collaboration strengthens Microcaps‘ encapsulation technology and its position as an innovator in the fragrance and beauty industry. Encapsulation technology plays a pivotal role in enhancing fragrance...
News 06.07.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an...